Biosynex signed a binding offer to acquire 100% of the stock in Avalun SAS, a company developing the Labpad in vitro diagnostic device that provides rapid biological test results from [...]
BIOSYNEX, which has established itself with the COVID-19 pandemic as a key player in decentralized biology, is highly complementary to AVALUN. Read more
As the HIV Conference begins in Amsterdam and brings together policy makers, the pharmaceutical industry and many associations from around the world, the TV report shows an increase in the [...]
Biosynex has the great pleasure to invite you to a conference focusing on selftesting and new rapid test developments (multiplexing).
Come and meet the Biosynex team booth n°3E42 at MEDICA trade fair in Düsseldorf.